EUVIMEDDescobrir EUVIMED
Übersichtsarbeit

Evolving medical treatment for vascular malformation

Calver Pang iD, Rebecca Lee, Rebecca Nisbet iD, George Hamilton, Jocelyn Brookes, Chung Sim Lim

Phlebology: The Journal of Venous Disease · 2025

DOI: 10.1177/02683555251361663 ↗

At a glance

Übersichtsarbeit in Phlebology: The Journal of Venous Disease, 2025. Written by Calver Pang and 5 co-authors. Institution: Department of Vascular Surgery, Royal Free London NHS Foundation Trust, London, UK. Major MEDLINE topics: Vascular Malformations, Angiogenesis Inhibitors. 80 references. Funded by: Royal Free Charity, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Butterfly AVM Charity.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Vascular malformations are abnormal growth or development of the vascular structure that result from genetic mutations during early vascular development. Traditional invasive treatment for vascular malformations includes embolo-sclerotherapy, cryotherapy, laser therapy and surgery. However, surgical or minimally invasive treatment is rarely optimal due to the risk of treatment complications, and a complete cure is often difficult to achieve. Targeted therapy can be guided by the current understanding of molecular signalling pathways and disease classifications. Existing and novel medical treatments target the major cellular signalling pathways implicated in the pathogenesis of vascular malformations: mTOR inhibitors, phosphatidylinositol-4,5-biphsophate 3-kinase catalytic subunit alpha (PIK3CA) inhibitors, and AKT inhibitors are being developed to target the Phosphoinositide 3-Kinase (PI3K)/AKT/mTOR pathway, while mitogen-activated protein kinase (MEK) inhibitors and BRAF inhibitor are being researched to target the RAS/RAF/MEK/ERK pathway. Angiogenesis inhibitors are also utilised in the treatment of vascular abnormalities. This review aims to discuss the evolving medical therapy available in the treatment of Vascular Malformations.

Subjects

MeSH terms (MEDLINE)

Vascular MalformationsAngiogenesis InhibitorsHumansMTOR InhibitorsSignal Transduction

Author keywords

Vascular malformationdrug therapygenetic mutationmedicinemolecular biologypharmacological therapy

Substances

Angiogenesis InhibitorsMTOR Inhibitors

Authors and institutions

  • Department of Vascular Surgery, Royal Free London NHS Foundation Trust, London, UK.
  • Department of Surgical Biotechnology, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
  • Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • School of Medicine, University of Leeds, Leeds, UK.
  • Department of Interventional Radiology, Royal Free London NHS Foundation Trust, London, UK.

ORCID profiles: Calver Pang, Rebecca Nisbet

Funding

  • Royal Free Charity
  • National Institute for Health Research University College London Hospitals Biomedical Research Centre
  • Butterfly AVM Charity

Cite

APA

Pang, C., Lee, R., Nisbet, R., Hamilton, G., Brookes, J., & Lim, C. S. (2025). Evolving medical treatment for vascular malformation. Phlebology: The Journal of Venous Disease. https://doi.org/10.1177/02683555251361663

Vancouver

Pang C, Lee R, Nisbet R, Hamilton G, Brookes J, Lim CS. Evolving medical treatment for vascular malformation. Phlebology: The Journal of Venous Disease. 2025. doi:10.1177/02683555251361663

BibTeX
@article{Pang2025,
  author = {Pang, Calver and Lee, Rebecca and Nisbet, Rebecca and Hamilton, George and Brookes, Jocelyn and Lim, Chung Sim},
  title = {Evolving medical treatment for vascular malformation},
  journal = {Phlebology: The Journal of Venous Disease},
  year = {2025},
  doi = {10.1177/02683555251361663}
}
Start for free →